Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies
1. 系统已在2025-06-23 15:32:22对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s0140-6736(25)00825-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625008256
其他信息:
出版社: Elsevier BV
作者: Beryl B Cummings; Mark P Joing; Page R Bouchard; Mark N Milton; Peter F Moesta; Vyas Ramanan; Andrew Lane; Joe Hirman; John W Trauger; Eleftheria Maratos-Flier; Andrei Voznesensky; Igor Splawski; Amitabh V Nimonkar; Meghan M Flaherty; B Alexander Yi; Daniel Meyers; Francois Huet; Sukhdeep K Sahambi; Denise P Yates; Douglas Hom; Markus Hinder; Craig T Basson; Chris O'Donnell; Evan S Siegelman; Chris E Garrett; Joshua Lehrer-Graiwer; Rebecca A Juliano; Ethan J Weiss
